{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:00:50Z","timestamp":1790100050681,"version":"4.0.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"name":"Institut National du Cancer"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To report safety outcomes of transscleral fine-needle aspiration biopsy (FNAB) followed by irradiation for uveal melanoma (UM) in a tertiary ocular oncology center over 10 years, and assess whether FNAB modified the overall prognosis of patients treated for primary UM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients treated for UM between 2009 and 2020, eligible for conservative treatments by proton beam radiotherapy or Iodine-125 brachytherapy and to FNAB performed before UM treatment (tumor thickness 5\u201310 mm), were included retrospectively. Patients who underwent FNAB were compared with nonbiopsied UM controls with similar characteristics, matched 1:1 using a propensity score. Complication rates, including local intraocular and extraocular relapse, metastases, and overall survival, were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 2,813 UM cases, 347 cases who underwent FNAB were matched to 347 controls. The median follow-up was 6.1 years (min = 0.2\u2013max=13.3). There was no difference in overall survival (OS) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.25) and metastasis-free interval (MFI,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.68). Twenty-four cases (6.9%) and 17 controls (4.9%) developed local intraocular recurrence (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.46). Extraocular relapses occurred in five cases (1.4%) and one control (0.3%), showing no statistical difference (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.12). Patients with monosomy 3 and chromosome 8 gain had significantly worse OS and MFI compared with those with normal 3 and 8 chromosomes, and to a lesser extent to those with either chromosomal alteration (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). Those with monosomy 3 and chromosome 8 gain experienced more local recurrences (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.013).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>FNAB seems safe in extraocular relapses, OS or MFI, but over the 2009 to 2020 period, accessing to primary UM somatic genetic features did not improve patient prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004906","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:01:27Z","timestamp":1781532087000},"page":"1781-1790","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["SAFETY AND OUTCOME OF TRANSSCLERAL FINE-NEEDLE ASPIRATION BIOPSY IN UVEAL MELANOMA"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2995-4579","authenticated-orcid":false,"given":"Alexandre","family":"Bourdin","sequence":"first","affiliation":[{"name":"Department of Ocular Oncology, Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Dureau","sequence":"additional","affiliation":[{"name":"Department of Biometry, Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Algret","sequence":"additional","affiliation":[{"name":"Department of Biometry, Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Malaise","sequence":"additional","affiliation":[{"name":"Department of Ocular Oncology, Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Lumbroso-Le Rouic","sequence":"additional","affiliation":[{"name":"Department of Ocular Oncology, Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Pierron","sequence":"additional","affiliation":[{"name":"Somatic Genetics Unit, Department of Genetics, Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"A\u00eft Rais","sequence":"additional","affiliation":[{"name":"Somatic Genetics Unit, Department of Genetics, Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Belkacem","sequence":"additional","affiliation":[{"name":"Department of Ocular Oncology, Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Piperno-Neumann","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institut Curie, Paris, France;"},{"name":"INSERM U830, \u201cDNA Repair and Uveal Melanoma (DRUM)\u201d, Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cassoux","sequence":"additional","affiliation":[{"name":"Department of Ocular Oncology, Institut Curie, Paris, France;"},{"name":"Universit\u00e9 Paris Cit\u00e9, Paris, France; and"},{"name":"INSERM UMR1138 \u201cFrom Physiopathology of Ocular Diseases to Clinical Developments\u201d, Centre de Recherche des Cordeliers, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9721-777X","authenticated-orcid":false,"given":"Alexandre","family":"Matet","sequence":"additional","affiliation":[{"name":"Department of Ocular Oncology, Institut Curie, Paris, France;"},{"name":"Universit\u00e9 Paris Cit\u00e9, Paris, France; and"},{"name":"INSERM UMR1138 \u201cFrom Physiopathology of Ocular Diseases to Clinical Developments\u201d, Centre de Recherche des Cordeliers, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260922","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ohc.2004.07.002","article-title":"Uveal melanoma: epidemiologic aspects","volume":"18","author":"Singh","year":"2005","journal-title":"Ophthalmol Clin North America"},{"key":"R2-20260922","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.31557\/APJCP.2022.23.5.1791","article-title":"Global incidence and trend of uveal melanoma from 1943-2015: a meta-analysis","volume":"23","author":"Naseripoor","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"R3-20260922","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"R4-20260922","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.hoc.2020.08.010","article-title":"Biology of melanoma","volume":"35","author":"Ostrowski","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"R5-20260922","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","article-title":"Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes","volume":"127","author":"Shields","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R6-20260922","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"R7-20260922","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djaa047","article-title":"Germline MBD4 mutations and predisposition to uveal melanoma","volume":"113","author":"Derrien","year":"2021","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"4","key":"R8-20260922","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jnci\/djad248","article-title":"Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variants","volume":"116","author":"Villy","year":"2024","journal-title":"JNCI J Natl Cancer Inst"},{"key":"R9-20260922","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000328257","article-title":"Treatment of uveal melanoma by accelerated proton beam","volume":"49","author":"Desjardins","year":"2011","journal-title":"Dev Ophthalmol"},{"key":"R10-20260922","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Investig Opthalmol Vis Sci"},{"key":"R11-20260922","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bjophthalmol-2013-303867","article-title":"Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma","volume":"98","author":"Cassoux","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R12-20260922","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.ophtha.2017.04.003","article-title":"Personalized prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8-Year period","volume":"124","author":"Shields","year":"2017","journal-title":"Ophthalmology"},{"key":"R13-20260922","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ajo.2015.11.005","article-title":"Fine needle aspiration biopsy in uveal melanoma: technique, complications, and outcomes","volume":"162","author":"Sellam","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R14-20260922","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/bjophthalmol-2015-306921","article-title":"Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications","volume":"100","author":"Singh","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R16-20260922","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3390\/cancers11081173","article-title":"Comparative cytogenetic abnormalities in paired choroidal melanoma samples obtained before and after proton beam irradiation by transscleral fine-needle aspiration biopsy and endoresection","volume":"11","author":"Matet","year":"2019","journal-title":"Cancers"},{"key":"R17-20260922","doi-asserted-by":"crossref","first-page":"111338","DOI":"10.1016\/j.jclinepi.2024.111338","article-title":"Use and reporting of inverse-probability-of-treatment weighting for multicategory treatments in medical research: a systematic review","volume":"170","author":"Bettega","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"R18-20260922","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s10792-023-02647-9","article-title":"Trans-scleral uveal melanoma biopsy: can it be safely and accurately incorporated into a medium volume ocular oncology service?","volume":"43","author":"O'Day","year":"2023","journal-title":"Int Ophthalmol"},{"key":"R19-20260922","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00417-019-04531-8","article-title":"Multi-center analysis of intraocular biopsy technique and outcomes for uveal melanoma: Ocular Oncology Study Consortium report 4","volume":"258","author":"Seider","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-20260922","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/aos.13858","article-title":"Intraocular biopsy of uveal melanoma risk assessment and identification of genetic prognostic markers","volume":"96","author":"Bagger","year":"2018","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R21-20260922","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ophtha.2011.08.046","article-title":"Multi-year Follow-up of fine-needle aspiration biopsy in choroidal melanoma","volume":"119","author":"McCannel","year":"2012","journal-title":"Ophthalmology"},{"key":"R22-20260922","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ophtha.2010.05.023","article-title":"Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens","volume":"118","author":"Shields","year":"2011","journal-title":"Ophthalmology"},{"key":"R23-20260922","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ophtha.2013.07.043","article-title":"The ocular consequences and applicability of minimally invasive 25-Gauge transvitreal retinochoroidal biopsy","volume":"120","author":"Bagger","year":"2013","journal-title":"Ophthalmology"},{"key":"R24-20260922","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ophtha.2018.03.011","article-title":"The cancer genome atlas project: an integrated molecular view of uveal melanoma","volume":"125","author":"Jager","year":"2018","journal-title":"Ophthalmology"},{"key":"R25-20260922","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1016\/j.xops.2022.100121","article-title":"Improved uveal melanoma copy number subtypes including an Ultra\u2013high-risk group","volume":"2","author":"Lalonde","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"R26-20260922","doi-asserted-by":"crossref","first-page":"100800","DOI":"10.1016\/j.preteyeres.2019.100800","article-title":"Uveal melanoma: towards a molecular understanding","volume":"75","author":"Smit","year":"2020","journal-title":"Prog Retin Eye Res"},{"key":"R27-20260922","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaophthalmol.2018.0561","article-title":"Yield, techniques, and complications of transvitreal and transscleral biopsies in small uveal melanoma","volume":"136","author":"Kim","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R28-20260922","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/jamaophthalmol.2013.2506","article-title":"Extraocular extension of uveal melanoma after fine-needle aspiration, vitrectomy, and open biopsy","volume":"131","author":"Schefler","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R29-20260922","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/ICB.0000000000000253","article-title":"Extraocular extension of ciliochoroidal melanoma after transscleral fine-needle aspiration BIOPSY","volume":"10","author":"Mashayekhi","year":"2016","journal-title":"Retin Cases Brief Rep"},{"key":"R30-20260922","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cncr.29727","article-title":"Uveal melanoma: from diagnosis to treatment and the science in between: uveal melanoma review","volume":"122","author":"Chattopadhyay","year":"2016","journal-title":"Cancer"},{"key":"R31-20260922","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"key":"R32-20260922","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"R33-20260922","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1200\/JCO.2017.35.15_suppl.9502","article-title":"A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ)","volume":"35","author":"Piperno-Neumann","year":"2017","journal-title":"J Clin Oncol"},{"key":"R34-20260922","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/bjophthalmol-2019-314461","article-title":"A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes","volume":"104","author":"Binkley","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R35-20260922","doi-asserted-by":"crossref","first-page":"976837","DOI":"10.3389\/fonc.2022.976837","article-title":"Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy","volume":"12","author":"Khan","year":"2022","journal-title":"Front Oncol"},{"key":"R36-20260922","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ophtha.2017.08.017","article-title":"Adjuvant sunitinib in high-risk patients with uveal melanoma","volume":"125","author":"Valsecchi","year":"2018","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:00:42Z","timestamp":1790096442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004906"}},"subtitle":["10-year Experience in 347 Cases"],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004906","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}